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Health Care for Mitochondrial Disorders
in Canada: A Survey of Physicians
Karen Paik, Matthew A. Lines, Pranesh Chakraborty, Sara D. Khangura, Maureen
Latocki, Walla Al-Hertani, Catherine Brunel-Guitton, Aneal Khan, Blaine Penny,
Cheryl Rockman-Greenberg, C. Anthony Rupar, Neal Sondheimer, Mark
Tarnopolsky, Kylie Tingley, Doug Coyle, Sarah Dyack, Annette Feigenbaum,
Michael T. Geraghty, Jane Gillis, Clara D. M. van Karnebeek, Jonathan B.
Kronick, Julian Little, Murray Potter, Komudi Siriwardena, Rebecca Sparkes,
Lesley A. Turner, Kumanan Wilson, Daniela Buhas, Beth K. Potter , in
collaboration with the Canadian Inherited Metabolic Diseases Research Network
ABSTRACT: Background: An improved understanding of diagnostic and treatment practices for patients with rare primary
mitochondrial disorders can support benchmarking against guidelines and establish priorities for evaluative research. We aimed to
describe physician care for patients with mitochondrial diseases in Canada, including variation in care. Methods: We conducted a crosssectional survey of Canadian physicians involved in the diagnosis and/or ongoing care of patients with mitochondrial diseases. We used
snowball sampling to identify potentially eligible participants, who were contacted by mail up to ﬁve times and invited to complete a
questionnaire by mail or internet. The questionnaire addressed: personal experience in providing care for mitochondrial disorders;
diagnostic and treatment practices; challenges in accessing tests or treatments; and views regarding research priorities. Results: We
received 58 survey responses (52% response rate). Most respondents (83%) reported spending 20% or less of their clinical practice time
caring for patients with mitochondrial disorders. We identiﬁed important variation in diagnostic care, although assessments frequently
reported as diagnostically helpful (e.g., brain magnetic resonance imaging, MRI/MR spectroscopy) were also recommended in published
guidelines. Approximately half (49%) of participants would recommend “mitochondrial cocktails” for all or most patients, but we
identiﬁed variation in responses regarding speciﬁc vitamins and cofactors. A majority of physicians recommended studies on the
development of effective therapies as the top research priority. Conclusions: While Canadian physicians’ views about diagnostic care and
disease management are aligned with published recommendations, important variations in care reﬂect persistent areas of uncertainty and a
need for empirical evidence to support and update standard protocols.

RÉSUMÉ: Les soins de santé prodigués au Canada à des individus atteints de troubles mitochondriaux : une enquête menée auprès de
médecins. Contexte: Dans le cas de patients atteints de troubles mitochondriaux rares, il est permis de croire qu’une meilleure compréhension des
pratiques en matière de diagnostic et de traitement peut contribuer, au moyen des lignes directrices, à l’étalonnage et à l’établissement de priorités en ce qui
regarde la recherche évaluative. Notre intention a été de décrire les soins prodigués au Canada par des médecins, notamment leur variabilité, dans le cas de
ces patients. Méthodes: Pour ce faire, nous avons effectué une enquête transversale auprès de médecins canadiens qui posent des diagnostics de troubles
mitochondriaux et qui prodiguent des soins continus aux patients qui en sont atteints. À cet effet, nous avons fait appel à la méthode d’enquête dite
« en boule de neige » (snowball sampling) aﬁn d’identiﬁer des participants possiblement admissibles. Ces derniers ont été ensuite contactés par la poste,
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et ce, à cinq reprises au maximum. Ils ont été invités à remplir un questionnaire et à le retourner par la poste ou en ligne. Ce questionnaire abordait les
aspects suivants : leur expérience personnelle à titre de prestataire de soins ; leurs pratiques en matière de diagnostic et de traitement ; les déﬁs se présentant
à eux au moment d’avoir accès à des tests ou à des traitements ; et ﬁnalement leurs points de vue en ce qui regarde les priorités de la recherche.
Résultats: Dans le cadre de cette enquête, nous avons reçu 58 réponses, ce qui représente un taux de 52 %. Une majorité de répondants (83 %) ont indiqué
allouer 20 % ou moins de leur temps de pratique clinique aux soins de patients atteints de ces troubles. Nous avons également noté d’importantes
variations concernant les soins et les diagnostics, et ce, même si les outils d’évaluation fréquemment considérés utiles sur le plan diagnostic (p. ex. : des
IRM du cerveau/la spectroscopie par RM) étaient également recommandés dans des lignes directrices déjà publiées. Environ la moitié de nos répondants
(49 %) recommanderaient volontiers un « cocktail » de vitamines pour tous leurs patients ou la plupart d’entre eux. Quand il est question de vitamines
spéciﬁques et de cofacteurs, nous avons cependant identiﬁé une variation dans leurs réponses. Interrogés quant à la priorité numéro un en matière de
recherche, une majorité de répondants a dit recommander la poursuite d’études portant sur la mise sur pied de traitements thérapeutiques efﬁcaces.
Conclusions: Bien que les points de vue de ces médecins canadiens en ce qui regarde les diagnostics et la prise en charge des troubles mitochondriaux
soient en phase avec des recommandations publiées, d’importantes variations reﬂètent la persistance d’aspects incertains ainsi qu’un besoin de données
empiriques aﬁn de renforcer et de mettre à jour les protocoles de rééférence.

Keywords: Mitochondrial disorder, Health services research, Survey

doi:10.1017/cjn.2019.240

BACKGROUND
Primary mitochondrial diseases are a heterogeneous group of
rare genetic disorders that can impair the respiratory transport
chain, structural components of proteins in mitochondrial
membranes, and mitochondrial DNA maintenance.1 As several
different protein complexes are responsible for the formation,
regulation, and function of the respiratory chain, there are a vast
number of nuclear DNA (nDNA) and mitochondrial DNA
(mtDNA) mutations that can contribute to clinical mitochondrial
disorders.2–4 There are a number of well-known clinical mitochondrial syndromes, such as mitochondrial encephalopathy with
lactic acidosis and stroke-like episodes (MELAS) and myoclonic
epilepsy and ragged-red ﬁber disease (MERRF), which both arise
from heteroplasmic point mutations in mtDNA; or Leigh syndrome, which can occur due to either mitochondrial or nuclear
gene mutations.5 Mitochondrial disorders typically affect multiple systems, particularly those whose functions are highly
dependent on aerobic metabolism, such as the nervous and
muscular systems.6 Possible clinical features include neurological manifestations such as ataxia, optic neuropathy, and seizures,
and multi-systemic features such as cardiomyopathy, hearing
loss, myopathy, ophthalmoplegia, gastrointestinal dysmotility
and function, and metabolic acidosis.5 Although evidence
regarding the epidemiology of mitochondrial disorders is sparse,
studies in Australia and England estimated a prevalence of
clinically diagnosed disease of at least 1 in 8000 to 1 in
16,000,7–9 with a higher prevalence of the presence of pathogenic
mtDNA or nDNA mutations.9
Due to the heterogeneity of the clinical features of different
mitochondrial disorders, the speciﬁc interventions used to
diagnose and treat patients vary widely and different medical
specialties, most notably neurologists or geneticists, provide
diagnostic care and ongoing disease management support.10
Few disease-speciﬁc interventions are available; examples of
treatments for mitochondrial diseases include exercise and diet
regimens, and vitamin “cocktails,” with evidence of variation in
treatment among providers.11 The Mitochondrial Medicine
Society (MMS) recently developed and published guidelines
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for the diagnosis and management of mitochondrial diseases12
and consensus standards for the ongoing care of diagnosed
patients.13 The guidelines were informed by a systematic review
of existing literature, and both the guidelines and care standards
were developed based on consensus methods involving experts
in mitochondrial medicine. While these recommendations are
likely to result in greater standardization of care for mitochondrial diseases, the authors acknowledge that much of this
guidance was not evidence-based, in part due to the low
prevalence of the individual mitochondrial disease syndromes,
which creates challenges in generating robust evidence to
inform best practices.
In order to improve diagnosis and treatment for patients with
mitochondrial diseases, there is an initial need to better understand
the organization of care. Understanding what care is currently
being provided and where there is heterogeneity in practice will
help to support benchmarking against published guidelines and
standards and to establish priorities for formal evaluative research
designed to determine which interventions are associated with best
outcomes for patients. Accordingly, we conducted a cross-sectional survey of Canadian physicians involved in the diagnosis and/or
provision of ongoing care to patients with mitochondrial diseases.
The three main objectives of this study were as follows:
(i) to describe care for patients with mitochondrial diseases in
Canada, with respect to the providers involved and
services provided;
(ii) to investigate variation in care, with respect to diagnostic
tests, patient monitoring, and management/treatment; and
(iii) to describe Canadian clinicians’ views on research
priorities for patients with mitochondrial diseases.

METHODS
The study protocol was approved by the Ottawa Health Sciences
Network Research Ethics Board (Protocol # 20160721-01H) and by
the Children’s Hospital of Eastern Ontario Research Ethics Board
(Protocol # 16/133X).
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Sample Selection and Survey Implementation
Our study population encompassed Canadian physicians with
interest and expertise in diagnosing and/or treating mitochondrial
disease. Because neither a single specialty nor professional
association comprehensively represents this group, we used
snowball sampling as the main method of participant identiﬁcation and recruitment.14 To develop the initial sampling frame, we
formed an advisory group of Canadian experts in mitochondrial
medicine who identiﬁed names of potential respondents based on
their professional networks. We also sampled from relevant
professional organizations and research networks with publicly
available membership lists, such as the American College of
Medical Genetics and Genomics and the Canadian Inherited
Metabolic Diseases Research Network. As part of survey completion, participants in the initial sample were asked to suggest
the names of potentially eligible and interested colleagues, who
then formed the snowball sample. They in turn had the option to
recommend other mitochondrial disease care providers for
recruitment in their responses.
Potential participants were invited to participate in the survey
by mail and could complete the survey by mail or internet.15,16 To
invite their participation, sampled physicians were contacted up
to ﬁve times in an approach modiﬁed from Dillman.17 These
contacts were spread out over a period of several weeks and
included: a pre-notiﬁcation letter about the study; a survey
package (cover letter, questionnaire booklet, $5 coffee shop gift
card, and postage-paid return envelope); a reminder letter for nonrespondents; and up to two further survey packages (without the
gift card) to remaining non-respondents. The cover letter included
with the survey package also provided a link to the online version
of the survey with an access code unique to the respondent. The
online version of the questionnaire was implemented using a
secure Research Electronic Data Capture (REDCap)18 database
housed at the Children’s Hospital of Eastern Ontario. The survey,
including multiple rounds of snowball sampling, was conducted
between December 2016 and July 2017.
Questionnaire
The questionnaire was developed by the study investigators
with some questions about demographics and practice characteristics adapted from the National Physician Survey.19 The survey
addressed the following topics: respondents’ personal experience
in care for patients with mitochondrial disorders; their views
regarding diagnostic, treatment, and care coordination/monitoring
practices; their research interests and priorities; and their personal
and practice characteristics.
Data Analysis
Paper survey data were entered into REDCap using double
data entry by experienced data clerks; discrepancies were identiﬁed and resolved by the ﬁrst author. We conducted descriptive
analysis, reporting proportions with 95% conﬁdence intervals.
We were interested in identifying tests and treatments characterized by high variability in their perceived usefulness among
physicians; following a previous publication,20 we deﬁned an
intervention as having high variability when 20% or more of
respondents indicated that they would ﬁnd the intervention
helpful in “all or most” cases, and 20% or more of respondents
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Table 1: Sample characteristics (N = 47)*
Characteristic

% (95% CI)

Has an active clinical practice in any area of medicine?

98 (94–100)

Spends any of their practice time engaged in the care of
patients with mitochondrial disorders (n = 45 responses)

89 (81–97)

Proportion of practice time dedicated to care of patients
with mitochondrial disorders (n = 40 responses)
1%–10%

60 (45–75)

11%–20%

23 (10–35)

21%–30%

5 (0–12)

31%–40%

8 (0–16)

41%–50%

5 (0–12)

Age (n = 46 responses)
35–44

46 (33–59)

45–54

33 (21–45)

55–64

13 (4–22)

65+

9 (2–16)

Province of main patient care setting (n = 43 responses)
Ontario

49 (34–64)

Québec

16 (5–27)

British Columbia

11 (2–21)

Alberta

9 (1–18)

Manitoba

7 (0–15)

Atlantic region

7 (0–15)

Nature of main patient population (n = 44 responses)
Urban/suburban

84 (73–95)

Rural or cannot identify a geographic population

16 (5–27)

Description of current work setting (not mutually
exclusive)
Academic health sciences center

96 (90–100)

University

38 (24–52)

Research unit

8 (0–16)

Other work setting†

11 (2–19)

Specialty (not mutually exclusive)
Medical genetics

72 (60–85)

General pediatrics

40 (26–54)

Medical biochemistry

17 (6–28)

Pediatric neurology

8 (0–16)

Other specialty‡

17 (6–28)

CI = conﬁdence interval.
*Not all proportions listed are out of 47, due to the variable number of
responses for each item.
†
Other work setting includes community health center, private ofﬁce/
clinic, non-academic health sciences center teaching hospital, community
hospital.
‡
Other specialty includes Adult Neurology, Diagnostic Radiology,
Pediatric Radiology, Neuroradiology, Adult Nephrology, Pediatric
Nephrology, Pain Medicine, Pediatric Critical Care Medicine, Internal
Medicine, Adult Endocrinology and Metabolism, Pediatric Endocrinology
and Metabolism, and Physical Medicine and Rehabilitation.
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Table 2: Respondents’ experience in treating mitochondrial disorders (N = 47)*
Proportion (95% CI) of respondents who treated patients with each presentation of
mitochondrial disorder
Type of genetically based mitochondrial
disorder
Any mitochondrial disorder

The past 12 months:

Not in the past 12 months, but in the
past 5 years:

88 (78–98)

5 (0–11)

“Classical” (named) clinical presentations
Leigh(-like) disease

60 (46–75)

26 (13–39)

Alpers syndrome

19 (6–32)

30 (15–44)

Congenital lactic acidosis

56 (41–71)

20 (7–32)

CPEO

52 (37–67)

17 (5–28)

MNGIE

24 (10–37)

16 (4–27)

Multiple symmetric lipomatosis

11 (1–21)

5 (0–13)

8 (0–17)

27 (13–41)

Kearns-Sayre syndrome

35 (20–50)

35 (20–50)

MELAS

69 (55–83)

19 (7–31)

MERRF

28 (13–42)

25 (11–39)

NARP

26 (11–40)

20 (7–33)

LHON

45 (30–60)

20 (8–32)

8 (0–17)

14 (3–25)

83 (72–95)

10 (1–18)

Pearson syndrome

Aminoglycoside-related sensorineural
hearing loss
Non-classical but clearly mitochondrial
(based on clinical and/or laboratory
features)

MNGIE = myoneurogastrointestinal disorder and encephalopathy; NARP = neuropathy, ataxia, and retinitis
pigmentosa; LHON = Leber’s hereditary optic neuropathy.
*Not all proportions listed are out of 47, due to the variable number of responses for each item. Valid responses
were received from at least 36 and up to 43 responses for each type of disorder.

indicated that they would ﬁnd the intervention helpful “in rare
cases” or “never.” Responses to selected open-ended questions
were coded by one researcher (KP) and veriﬁed by a second
researcher (BKP). In some cases, to avoid reporting identifying
information about participants, responses were grouped into
categories representing the diverse regions of Canada including
the west coast, the Prairie Provinces, central Canada, and the
Atlantic region.
RESULTS

mitochondrial disorders, 83% reported spending 20% or less of
their clinical practice time, and 100% reported spending 50% or
less of their clinical practice time caring for patients with
mitochondrial disorders. Participants’ ages ranged from 35 to
over 65 years and they reported practicing mainly in universities
or academic health sciences centers, in seven different provinces
in Canada. Most (84%) reported practicing in urban/suburban
settings (Table 1). The majority of respondents identiﬁed themselves as specialists in medical genetics (72%) with general
pediatrics as the next most common specialty (40%).

Response Rate and Sample Characteristics
From our initial sample of 90 physicians, we obtained the
names of an additional 22 physicians through snowball sampling.
We received 58 responses (response rate: 58/112 = 52%). Among
the 58 responses, 47 were returned by mail and 11 were completed online. Forty-seven respondents (81%) provided useable
data and reported an interest in the diagnosis or management of
mitochondrial disorders and thus completed the entire survey.
The remainder of the results are based on the responses of those
47 participants.
Nearly all respondents reported having an active clinical
practice, with 89% spending any of their practice time engaged
in the care of patients with mitochondrial disorders (Table 1). Of
participants spending any time engaged in caring for patients with
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Clinical Experience with Mitochondrial Disorders
The vast majority of participants (37/42 responding to the
question) reported providing care for patients with any type of
mitochondrial disorder in the past 12 months. Non-classical but
clearly mitochondrial (based on clinical and/or laboratory features) disorders were reported as the most commonly treated
disorders within the past year (83%) (Table 2). Other disorders
treated by a majority of respondents in the past year were
MELAS (69%), Leigh-like disease (60%), congenital lactic
acidosis (56%), and chronic progressive external ophthalmoplegia syndrome (CPEO) (52%). All disorders we asked about had
been treated by at least 16% of the respondents in the past year or
past 5 years (Table 2).

LE JOURNAL CANADIEN DES SCIENCES NEUROLOGIQUES

A

B

Figure 1: Physicians’ responses regarding the perceived helpfulness of non-genetic diagnostic assessments in the investigation for a suspected mitochondrial disorder (percent of respondents).

Diagnostic Practices
Nearly all participants who completed the survey reported
having provided a diagnostic workup for a patient suspected to
have a mitochondrial disorder within the past 5 years, and about
half (53%) reported following a speciﬁc diagnostic algorithm.
Participants were asked to evaluate various diagnostic investigations according to how diagnostically helpful they were
considered to be, i.e., in all or most cases, in some cases, in
rare cases, or never (respondents could also select “would be
helpful but not available”; these responses were reported separately and removed from the denominator when reporting on
views about helpfulness). The only non-genetic diagnostic
investigation that was endorsed as “helpful in all or most cases”
by a majority of participants was brain magnetic resonance
imaging (MRI)/MR spectroscopy (61%); the next most endorsed
non-genetic assessment was lactate (44%) (Figure 1). Based on
our a priori deﬁnition of “high variability” in physician endorsement (see Methods), blood gases, acylcarnitine proﬁle, skin
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biopsy for ﬁbroblast culture, and one muscle biopsy technique
(Bergstrom needle) were assessments with high variability in
physician ratings of helpfulness (Figure 1). No non-genetic
diagnostic assessments were reported as “potentially helpful but
not available” by a majority of respondents (not shown in ﬁgure).
The two assessments most commonly reported as unavailable
were both muscle biopsy assessments: suction needle (Bergstrom)
(34%) and needle biopsy (47%).
A majority of participants (75%) reported using genetic/
genomic testing as part of the diagnostic process in 75% or
more of their patients with suspected mitochondrial disorders.
When asked to estimate the proportion of patients for whom
genetic/genomic testing was used as a ﬁrst-line diagnostic investigation, responses were variable: 28% of respondents reported
using genetic testing ahead of any other diagnostic investigations
in fewer than 25% of their patients, 14% reported using it for
25%–49% of their patients, 28% reported using it for 50%–74%
of their patients, and 30% reported using it for 75% or more of
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Figure 2: Physicians’ responses regarding the perceived helpfulness of genetic diagnostic assessments in
the investigation for a suspected mitochondrial disorder (percent of respondents).

their patients. Despite the wide use of genetic/genomic testing,
most respondents (79%) reported having identiﬁed the causative
mutation in fewer than 50% of their patients. There seemed to be
a greater degree of consensus among respondents concerning the
perceived helpfulness of various genetic/genomic assessments
relative to non-genetic diagnostic assessments: when 20% or
more of respondents endorsed a genetic/genomic assessment as
helpful in all or most cases, few reported it to be helpful rarely or
never (Figure 2). The most highly endorsed genetic/genomic
assessments, which were reported as helpful in all or most cases
by 36% and 33% of respondents, respectively, were next-generation
sequencing (NGS) of the entire mitochondrial genome, and
mtDNA testing using muscle tissue. Only one assessment, single
gene tests, was indicated by a majority of respondents (51%) to
be rarely or never helpful. No genetic/genomic tests were
reported as “potentially helpful but not available” by more than
20% of respondents (not shown in ﬁgure). The two genetic/
genomic assessments most commonly reported as unavailable
were whole exome sequencing (16%) and mtDNA testing using
urinary sediment (14%). Respondents who reported a lack of
availability of urinary sediment mtDNA testing were from
Ontario and British Columbia, while those who reported poor
availability of whole exome sequencing were from Alberta,
Manitoba, and Quebec.
Respondents were also asked generally about the availability
of diagnostic methods and their coverage by provincial health
insurance. At least 50% of respondents in all Canadian regions
(the west coast, the Prairie Provinces, central Canada, and the
Atlantic region) reported challenges associated with the availability and/or coverage of the diagnostic investigations they
would like to use. A frequently reported challenge, according
to survey respondents, was a lack of provincial funding, creating
barriers to accessing tests such as whole exome sequencing,
NGS, gene panels, and muscle biopsies. Other challenges included the lengthy process to request funding, or that testing must be
sent out of the province or the country; this latter barrier was
mentioned by nine respondents. Concerns about accessing whole
exome sequencing in particular were shared by 11 respondents.
About a quarter (26%) of physicians who participated in the
survey also reported that 50% or more of their patients with
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suspected mitochondrial disorders were in a later stage of disease
progression at their ﬁrst encounter. When asked what they
considered to be the single most signiﬁcant barrier to the clinical
recognition of mitochondrial diseases in patients presenting with
compatible symptoms, 71% chose non-speciﬁc symptoms. Most
of the remaining participants (20%) chose the broad differential
diagnosis. As the most important barrier to the speciﬁc genetic
diagnosis of a patient’s mitochondrial disorder, most respondents
chose non-speciﬁc symptoms (29%), the broad differential diagnosis (27%), or poor availability of molecular diagnostic investigations (24%). As open-ended responses, other participants
noted barriers related to disorders that may be missed by gene
panels or whole exome sequencing; the scope and invasiveness of
investigations; the use of less robust investigations which may
provide confusing results; and turnaround time for whole exome
sequencing.
Patient Monitoring and Organization of Care
Most participants reported having provided clinical care for
patients with mitochondrial disorders within the past 5 years
(87%). These respondents were asked to evaluate various monitoring evaluations for mitochondrial disorders according to whether they would use an evaluation routinely “for all or most patients,”
“for some patients,” “in rare cases,” or “never.” The most highly
endorsed evaluations, which the greatest proportions of respondents said they would use routinely for all or most of patients, were
growth parameters (83%), lactate (78%), “in clinic” developmental
assessment (75%), plasma amino acids (66%), and periodic echocardiography (66%) (Figure 3). There were two evaluations that a
relatively high (but minority) proportion of respondents stated they
would rarely or never use: plasma 3-methylglutaconic acid tests
(49%) and formal neuropsychological assessment (48%). Six
monitoring evaluations met our criterion for reﬂecting “high
variability in physician endorsement”: electroencephalography,
Holter monitor, HbA1c, creatinine clearance, acylcarnitine proﬁle,
and free/total carnitine (Figure 3).
Respondents were also asked about the coordination of routine
care of patients diagnosed with mitochondrial disorders in their
clinical practices. Seventy-one percentage of respondents, who were
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Figure 3: Physicians’ responses regarding the perceived helpfulness of evaluations used to routinely
monitor patients diagnosed with mitochondrial disorders (percent of respondents).

Figure 4: Physicians’ responses regarding the perceived helpfulness of mitochondrial cocktails and single
vitamins/cofactors (as part of a cocktail, or separately) for the treatment of patients with mitochondrial
disorders (percent of respondents).

from all of the regions represented in this survey, reported following
any form of an inter-professional care model. When asked to further
elaborate on the models in use at their clinics, respondents described
collaborating with providers of various disciplines, such as nurse
practitioners, dietitians, genetic counsellors, physiotherapists, occupational therapists, psychologists, and social workers. Some respondents described collaborating with other physicians of various
specialties within their clinics as well, listing geneticists, pediatricians, neurologists, respirologists, and orthopedic surgeons. In
contrast to the large proportion of respondents who indicted the
use of an inter-professional model of care, just 40% of respondents,
who were exclusively from central Canada or the Prairie Provinces,
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reported having a care coordination team at their center to which
they can refer patients with mitochondrial disorders.
Treatment Practices
Respondents were asked whether they recommend mitochondrial cocktails and single vitamins/cofactors for patients
with mitochondrial disorders, for “all or most patients,” “some
patients,” “in rare cases,” or “never.” Responses were variable:
while 49% would recommend cocktails for all or most patients,
17% would recommend cocktails in rare cases or never (Figure 4).
When those who recommend cocktails more than “never”
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were asked to describe the three mitochondrial cocktails that
they recommend most frequently, respondents listed a wide
variety of combinations that typically included three to ﬁve of
the following components (some components were reported
for only certain disease-speciﬁc cocktails): coenzyme Q10
(ubiquinone), creatine, alpha-lipoic acid, ascorbic acid,
vitamin E, thiamin, riboﬂavin, arginine, and citrulline. The
most highly endorsed single vitamins/cofactors, which greater
than 30% of respondents said they would recommend for all or
most patients, were ubiquinone, riboﬂavin, alpha-lipoic acid,
and carnitine (Figure 4). Four single vitamins/cofactors met
our criterion for “high variability in physician endorsement”:
creatine, carnitine, alpha-lipoic acid, and ascorbic acid.
Respondents reported that their patients typically access most
of the compounds in the mitochondrial cocktails they use as overthe-counter supplements (i.e., non-prescription products), or as
licensed drugs. When asked about the availability and coverage
of cocktails and/or their components, participants’ responses
were variable: 25% reported that all or most of the cocktails
they use are available to patients and covered by public insurance.
A further 20% reported challenges associated with availability,
28% reported challenges associated with coverage, and 25%
reported challenges associated with both availability and coverage of mitochondrial cocktails or their components. Respondents
who reported challenges in access to mitochondrial cocktails
were located in all of the provinces represented in this survey.
Regarding other interventions for the management of primary
mitochondrial disorders, a majority of respondents stated that
they would recommend smoking cessation or prevention (75%),
avoidance of potentially mitotoxic drugs (78%), and regular
moderate exercise (73%) to all or most of their patients. As
examples of potentially mitotoxic drugs for patients to avoid,
respondents listed propofol, aminoglycosides, valproic acid,
halogenated inhaled anesthetics, statins, aspirin, and corticosteroids.
Research Interests and Priorities
About half (49%) of the respondents reported having been
involved as an investigator in research related to mitochondrial
disorders in the past 5 years. This research consisted of case
reports (n = 17), basic research on mitochondrial function (n = 9),
and natural history studies (n = 8), as well as development of
diagnostics (n = 7), therapies (n = 3), drug development research
(n = 4), and clinical trials (n = 4). When asked about the three
research areas that are most important to improve outcomes for
patients with mitochondrial disorders as an open-ended question,
the most common response, suggested by 26 respondents, was for
research to develop effective therapies: 11 respondents listed
drug development or research on the efﬁcacy of cocktails,
supplements, and vitamins; 10 respondents suggested studies on
speciﬁcity and efﬁcacy of gene therapies; and 5 respondents
suggested studies on the impact of exercise and its therapeutic
potential. Other common suggestions included research to
improve biomarkers for disease monitoring and diagnosis, and
diagnostic markers for speciﬁc mitochondrial disorders.
DISCUSSION
We identiﬁed variation in practice among Canadian physicians
providing diagnostic and management care for suspected and
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conﬁrmed primary mitochondrial disease. With respect to diagnosis, no speciﬁc diagnostic evaluation was endorsed by an overwhelming majority of respondents for use in all or most cases. This
is likely in part a consequence of the heterogeneous nature of
mitochondrial disorders, with investigations dependent on speciﬁc
pathologies.21 In cases where participants’ opinions of a diagnostic
assessment reﬂected a relatively higher consensus, they generally
aligned with the recent MMS guidelines.12 For example, assessments that were regarded positively by a relatively high proportion
of respondents, such as brain MRI/MR spectroscopy, lactate,
NGS-based sequencing of the full mitochondrial genome, and
using muscle tissue for mtDNA testing, were all recommended in
the MMS statement; and the one diagnostic assessment that was
seen by the majority of respondents to be never or rarely helpful,
single gene tests, was discouraged in the guidelines12 Acylcarnitine
analysis, which was noted by the MMS guideline authors to have
little empirical support despite its being commonly recommended
elsewhere as a diagnostic evaluation,12 met our criterion for high
variability in physician endorsement. Our ﬁndings thus suggest
that Canadian mitochondrial physicians have views that generally
align with established recommendations but that there remains a
need for further evidence to better support decision-making about
diagnostic care. This need for evidence is reinforced by our ﬁnding
that nearly 80% of participants estimated that they identify the
mutations responsible for mitochondrial disease in only a minority
of their patients.
Generating evidence to establish the clinical validity of diagnostic tests and test strategies for mitochondrial disease is
challenging due to both the rarity of speciﬁc diseases or syndromes and the absence in many cases of a reference standard that
can be used to evaluate emerging tests. Future evaluative studies
should follow established principles for assessing diagnostic test
accuracy wherever possible, for example, using prospective study
designs that enroll unselected patients (e.g., random or sequential
patients suspected of a mitochondrial disease) and ensuring
comparable follow-up.22,23 Stratiﬁcation by phenotype may be
important as the value of particular diagnostic strategies may
differ depending on clinical manifestations and patient characteristics. In addition to evaluating the clinical validity of diagnostic
tests using metrics such as sensitivity, speciﬁcity, and diagnostic
utility (ability of a testing strategy to eventually lead to an
etiologic diagnosis), future studies could also evaluate which
sequence of ordering of tests leads to the most timely diagnoses
for particular presenting characteristics. Studies should also
investigate the clinical utility of diagnostic approaches with
respect to associations between changes to diagnostic care and
changes to disease management and/or patient and familycentered outcomes.24
Some survey respondents reported challenges associated with
the availability or coverage of diagnostic assessments, with 24%
of respondents identifying poor availability of molecular diagnostic investigations as the most important barrier to patients
receiving a speciﬁc genetic diagnosis. Despite these perceived
barriers, we note that a full range of diagnostic services are
currently available with cost coverage through major Canadian
academic health sciences centers that have specialist expertise in
mitochondrial disorders. It may be that perceived barriers related
to the access and availability of some tests, including administrative barriers that result in delays to accessing tests, differ
depending on the size or other characteristics of speciﬁc centers.
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However, we were unable to investigate perceptions of diagnostic
test availability within speciﬁc cities or hospitals due to our small
sample size. We note that 49% of respondents were from Ontario,
where mtDNA sequencing by NGS as well as NGS for nuclear
genes affecting the mitochondria are currently available and
provincially supported.
Challenges related to the non-speciﬁc symptoms and broad
differential diagnosis were cited as the most important barriers to
achieving a speciﬁc genetic diagnosis of mitochondrial disease by
29% and 27% of respondents, respectively. In addition, more than
one quarter of participating physicians reported that a majority of
their patients with suspected mitochondrial disorders were in a later
stage of disease progression at their ﬁrst encounter. Collectively,
these ﬁndings regarding the views of physicians about the challenges in diagnosing mitochondrial disorders corroborate the
results of a recent survey describing the “diagnostic odyssey” of
215 patients or family members of patients25; in that study, patients
consulted a median of ﬁve physicians during the diagnostic process
and a majority had received at least one non-mitochondrial
diagnosis before being diagnosed with mitochondrial disease.
Prospective patient-level data, for example from a representative
cohort, documenting the time from the onset of ﬁrst symptoms to
care-seeking contact, and to the ﬁnal diagnosis, is currently
unavailable but would be helpful for further elucidating the
diagnostic journey and evaluating changes to diagnostic care.
In addition to the diagnostic odyssey, patients with mitochondrial disorders frequently face challenges related to their high
needs for health services across multiple medical specialties, with
coordinated multidisciplinary care recognized as important from
the perspectives of patients/families26 and providers.13 While a
majority of physicians participating in our survey reported following an inter-professional model of care (71%), only 40%
perceived an ability to refer patients with mitochondrial disorders
to a care coordination team. This may be a particularly important
barrier for patients and their families given our ﬁnding that most
physicians spend a limited amount of their clinical time caring for
patients with mitochondrial disease; many individual institutions
may thus not have extensive and centralized expertise about the
needs of this rare disease population. According to a recently
published online catalogue, at least 11 tertiary care pediatric
centers in Canada have some form of complex care service
provision available although not all involve complex care clinics
or coordinators and criteria for accessing services vary.27 Further
research is needed to better understand the experiences with care
of patients with mitochondrial disorders and their families,
including their needs for and access to coordination services as
well as their experiences with diagnostic care and perceptions
about priority gaps in care.
With respect to disease management, just under half (49%) of
physicians participating in our survey reported that they would
recommend mitochondrial cocktails for all or most patients, with
variation in responses regarding speciﬁc vitamins and cofactors
as either ingredients in cocktails or as single interventions. While
acknowledging a 2012 Cochrane review that identiﬁed no strong
evidence in support of the efﬁcacy of vitamins and cofactors,6 the
MMS consensus guidelines recommend offering coenzyme
Q10/ubiquinone, alpha-lipoic acid, and riboﬂavin to all individuals
with mitochondrial disorders,12 corresponding to the three most
highly endorsed single vitamins/cofactors among our survey
respondents. Nearly three quarters (73%) of respondents also
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noted that they would recommend regular moderate exercise to
all or most individuals with mitochondrial disorders, consistent
with the guidelines.12 Thus, as with diagnostic testing, Canadian
physicians’ views on treatment for mitochondrial disease are
generally aligned with established recommendations. Our survey
respondents also recognized the absence of strong evidence in
support of all therapies for mitochondrial disease, with a majority
of participants citing studies on the development of effective
therapies as the top research priority in the ﬁeld. Notably, 20%
of survey respondents reported challenges associated with availability, 28% reported challenges associated with coverage, and
25% reported challenges associated with both availability and
coverage of mitochondrial cocktails or their components.
This study is the ﬁrst survey of Canadian physicians who
diagnose and manage primary mitochondrial disorders and contributes important information about the organization of care and
use of speciﬁc diagnostic and treatment strategies. However, the
ﬁndings should be interpreted in light of some limitations. For
example, our non-random sampling strategy and non-response of
close to half of sampled physicians may have created selection bias
so that our ﬁndings may not represent all Canadian physicians
involved in care for mitochondrial disorders. We did not collect
information about non-respondents, rendering it challenging to
evaluate this possibility. A related issue was our small sample size,
which meant we were unable to investigate systematic differences
in responses according to physician specialty; views from specialties other than medical genetics and general pediatrics (which
made up the majority of specialties in our participant population)
may not be well reﬂected in our ﬁndings. Furthermore, it is
possible that different respondents interpreted the questions differently, particularly when asked to indicate how helpful different
interventions were likely to be, given the inherently subjective
nature of the response choices. While this question format was
necessary due to the heterogeneity of mitochondrial disorders, our
a priori deﬁnition of high variation in physician endorsement
allowed us to identify key areas of uncertainty. Finally, results
from this survey provide only a partial perspective regarding the
nature of challenges associated with the diagnosis and ongoing
care of mitochondrial disorders. Studies that seek to understand the
patient and family perspective on these issues would add important
information to the results reported here, particularly given that the
aspects of disease and care that are prioritized by patients may
differ from those prioritized by clinicians.28
CONCLUSIONS
Perhaps due to the relatively low incidence of each type of
disorder, the nature of care and variation in care provided for
individuals with mitochondrial disorders in Canada has not been
well documented to date. Our ﬁndings indicate that while Canadian physicians’ views about diagnostic care and disease management are aligned with published recommendations, there are
important variations in care that reﬂect persistent areas of uncertainty. In order to support the development and updating of
standard protocols and encourage best practices, our results
underscore the need for well-designed investigations of the
diagnostic accuracy of biochemical, imaging, and genetic-genomic
assessments and of the clinical efﬁcacy of various treatments,
including mitochondrial cocktails and their components for this
large group of rare diseases. Future research should also
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incorporate the patient and family perspective regarding experiences with both diagnostic care and ongoing management, with
particular attention to care coordination needs.
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